223 related articles for article (PubMed ID: 32413119)
1. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Di Stefano AL; Picca A; Saragoussi E; Bielle F; Ducray F; Villa C; Eoli M; Paterra R; Bellu L; Mathon B; Capelle L; Bourg V; Gloaguen A; Philippe C; Frouin V; Schmitt Y; Lerond J; Leclerc J; Lasorella A; Iavarone A; Mokhtari K; Savatovsky J; Alentorn A; Sanson M;
Neuro Oncol; 2020 Nov; 22(11):1614-1624. PubMed ID: 32413119
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract][Full Text] [Related]
3. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
4. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
5. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and Molecular Characteristics of
Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
[TBL] [Abstract][Full Text] [Related]
7. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract][Full Text] [Related]
9. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.
Ballester LY; Moghadamtousi SZ; Leeds NE; Huse JT; Fuller GN
Acta Neuropathol Commun; 2019 Apr; 7(1):63. PubMed ID: 31036092
[No Abstract] [Full Text] [Related]
10. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
[TBL] [Abstract][Full Text] [Related]
11. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
12. Can adult
Gilani A; Davies KD; Kleinschmidt-DeMasters BK
Clin Neuropathol; 2021; 40(3):165-167. PubMed ID: 33769273
[No Abstract] [Full Text] [Related]
13. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
14. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
[TBL] [Abstract][Full Text] [Related]
15. Radiomic features predict Ki-67 expression level and survival in lower grade gliomas.
Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Liu X; Wang Y; Jiang T
J Neurooncol; 2017 Nov; 135(2):317-324. PubMed ID: 28900812
[TBL] [Abstract][Full Text] [Related]
16. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.
Li Y; Liu X; Qian Z; Sun Z; Xu K; Wang K; Fan X; Zhang Z; Li S; Wang Y; Jiang T
Eur Radiol; 2018 Jul; 28(7):2960-2968. PubMed ID: 29404769
[TBL] [Abstract][Full Text] [Related]
17. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
Gött H; Uhl E
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
19. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
20. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]